DISCUSSION: Curcuma longa is traditionally used in Herbal medicine as an anti-inflammatory to help relieve joint pain and provides antioxidants for the maintenance of good health.
|NPN (what's this?)||Product Code||Size||Per Capsule||Vegetarian|
|80034700||AOR04247||60 Vegi-Caps||133.3 mg||Vegetarian|
|Serving Size: 1 Capsule|
|Longvida® Optimized Curcumin* (from Curcuma longa root 25-30:1)||133.3 mg|
|Non-medicinal ingredients: ascorbyl palmitate, microcrystalline cellulose, soy lecithin, stearic acid, maltodextrin, silicon dioxide. Capsule: hypromellose. *LONGVIDA® is a registered trademark of Verdure Sciences Inc. International patent pending.|
AOR Guarantees: that no ingredients not listed on the label have been added to the product. Contains no wheat, gluten, nuts, peanuts, sesame seeds, sulphites, mustard, eggs, dairy, fish, shellfish or any animal byproduct.
Adult Dosage: Take 1 to 2 capsules daily, or as directed by a qualified health care practitioner.
Cautions: Consult a health care practitioner prior to use if you are taking antiplatelet medication or blood thinners, or if you have gallstones, a bile duct obstruction, stomach ulcers or excess stomach acid. Consult a health care practitioner if symptoms persist or worsen.
Pregnancy/Nursing: Consult a health care practitioner prior to use
100% pure curcumin from Longvida® Optimized Curcumin
The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.
Read More ...
Do Not Confuse Turmeric Root with Curcumin!
Curcumin is a powerful anti-inflammatory derived from turmeric root. Due to its widespread mechanisms of action, curcumin has been studied for conditions such as cancer, Alzheimer’s disease, irritable bowel disease (IBD), colitis, diabetes, rheumatoid arthritis, viral infections such as hepatitis, drug-resistant bacterial infections, healing of skin conditions, and more.
Researchers recommend taking a dose of 3 to 4 g of 95% curcumin per day in order to obtain any health benefits like pain relief, inflammation reduction, or improvements to heart health or diabetes. This 3-4 g dose is equivalent to taking 7 to 10 capsules of curcumin 95%, or between twenty to thirty capsules of a high potency 750 mg 10:1 ratio extract of turmeric root! Clearly taking this amount of capsules per day is unreasonable.
Longvida®, a highly bioavailable form of curcumin, is the result of testing over two hundred formulations and has taken more than ten years to develop. In a human study on cancer patients, Longvida® curcumin was shown to be over 100 times more bioavailable than regular curcumin. This formulation was developed and patented by UCLA Medical School and is licensed exclusively to Advanced Orthomolecular Research (AOR).
Other benefits are:
Turmeric root supplements absolutely do not offer the same benefits as those containing isolated curcumin. Curcumin is the most potent component of the turmeric root. Unfortunately, turmeric root contains less than 2% of curcumin making it ineffective for any health benefits. In addition, over 95% of all clinical studies have been conducted using isolated curcumin and NOT with the turmeric root. Even 750mg of a 10:1 ratio extract of turmeric will deliver no more than 150mg of the active curcumin. But given the poor bioavailability (the amount of the active compound that reaches the target site or site of action) of this compound, the amount you actually get is likely far less than that. Clinical studies suggest that the bioavailability is less than 5%, making even standard 95% curcumin formulations fairly ineffective. As for a significantly weakened turmeric root formula? That becomes essentially useless!
Curcumin is currently being heavily studied for use as an adjunct to conventional cancer treatments. Unfortunately, most of the studies have noted minimal results despite promising in vitro and animal studies. Researchers have recognized that the cause for the poor results is curcumin’s poor bioavailability.
Gota and colleagues did a safety and bioavailability study on healthy volunteers and patients with non-responsive bone cancer. Subjects were given doses between 400 and 1,200 mg of curcumin in solid lipid particle form (equivalent to 3 to 9 capsules of Curcumin Active). All doses showed significant absorption into the bloodstream over 8 hours with no adverse events. This is especially significant since previous studies giving 8,000-12,000 mg of pure regular curcumin barely showed any blood levels or clinical improvements. In addition, the 1,200 mg dose produced blood levels of curcumin necessary to reduce isoprostanes, TNF-α, and amyloid-β, which are markers for diseases like cancer and Alzheimer’s disease.
There is also significant interest in its ability to reduce amyloid-β plaque, which is thought to be a causative factor of Alzheimer’s disease. In vitro and animal studies have shown that curcumin can significantly reduce levels of amyloid-β and preserve Alzheimer model animal memory. Finally, a recent human study has shown that just 80 mg of curcumin can reduce amyloid-β in humans. The curcumin that was finally able to do so was Longvida® curcumin SLP, and in just one month.
Longvida® Curcumin in Humans
A human trial on curcumin showed statistically significant effects on clinical endpoints in a healthy population. The fact that such a low dose (80 mg) was needed to achieve effects in only 30 days is an interesting and unique finding as well, and adds to the substantial amount of pharmacokinetic and pharmacodynamic data compiled on Longvida®. The results of the study suggest that curcumin can produce beneficial effects in people who are without immediate disease states. The study was conducted on 38 healthy middle aged people between the age of 40 and 60 who were either given a dose of 80 mg/day of Longvida® curcumin extract for four weeks or were a part of the 19 person placebo group. The study is particularly interesting because the relatively small dose of curcumin, from Longvida® which was used, exerted a variety of health promoting effects leading researchers to presume that a significant amount of the curcumin was absorbed, although not tested directly.
Blood sample readings collected from test subjects to assess nitric oxide and sICAM molecules which are relevant to assessing cardiovascular risk and related to blood pressure and atherosclerosis, were notably affected by the curcumin. Both readings corresponded to a decreased risk of cardiovascular disease. The study also indicated that curcumin may have a positive effect on liver health maintenance as was noted from the reduction of indicators used to mark liver injury. Participants had lowered levels of triglycerides which relates to other research demonstrating that cholesterol could potentially be lowered in relatively healthy persons given higher dosages of the substance, thus benefiting those with or at risk of having cardiovascular disease.
Interestingly, other markers of inflammation and free radicals/toxic species that cause inflammation and damage to cells were also significantly lowered. Both direct and indirect antioxidant actions of curcumin were evident in the subjects; these findings are consistent with in vitro and animal studies used to measure increases in curcumin induced antioxidant enzyme activity.
Numerous supplements on the market contain the curcumin extract of turmeric. However, many of these are poorly absorbed and offer little value in terms of therapeutic benefit due to their poor bioavailability.
New Technology – Better Products!
Over the last ten years a great deal of research has been done to develop formulations that improve the bioavailability of curcumin. The goal has been to deliver more of the active molecules to the body in a much lower daily dose; as few as one to three capsules per day. There have been a number of technologies developed, but the one that has provided the most compelling evidence is nano-technology.
Longvida® curcumin was introduced to Canada exclusively by AOR in 2011. Curcumin Active is clinically proven to deliver several health benefits as a result of its higher bioavailability over regular curcumin supplements and has the following advantages:
Curcumin Active TM consists of solid lipid particles (SLP) which are tiny nano-sized (1 billionth of a meter) particles that have a protected layer that provides a phenomenal increase in stability, potency and effectiveness. Unlike regular curcumin that is easily broken down by stomach acids, Curcumin Fast Relief particles are resistant to acid breakdown. Even more important is the fact that these tiny particles are absorbed very rapidly. This means that they deliver all of the health benefits of curcumin, including pain relief, reduced inflammation, antioxidant properties and other effects much faster than any other curcumin product.
Try Curcumin Active TM today and start feeling the benefits of a real high-potency, high-bioavailability curcumin supplement.
Begum et al. Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer’s Disease. J Pharmacol Exp Ther. 2008 Jul;326(1):196-208.
Dadhaniya P, Patel C, Muchhara J, Bhadja N, Mathuria N, Vachhani K, Soni MG. Chronic safety of Longvida. Food Chem Toxicol. 2011 May 6.
Disilvestro RA, Joseph E, Zhao S, Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J. 2012 Sep 26;11:79.
Frautschy, SA. Bioavailability, brain concentrations, activity and dose-response of Longvida® SLCP. 38th Annual Meeting of the Society of Neuroscience , Washington DC, November 15, 2008.
Frautschy, SA et al. Omega 3 DHA and a bioavailable curcumin formulation synergize for Alzheimer prevention. 39th Annual Meeting of the Society of Neuroscience , Chicago, IL October 2009.
Frautschy, SA et al. Efficacy of Longvida® in relation to systemic availability in the brain. 39th Annual Meeting of the Society of Neuroscience , Chicago, IL October 2009.
Gota et al. afety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Ag Food Chem 2010 58(4): 2095-2099.
Ray B, Lahiri DK. Neuroinflammation in Alzheimer’s disease: different molecular targets and potential therapeutic agents including curcumin. Curr Opin Pharmacol. 2009 Aug;9(4):434-44.
Q: Why does AOR still offer Curcumin-95 if Longvida® curcumin is better?
A: There will always be consumers who abide by holistic philosophy and prefer pure, natural extracts that have not been modified or altered by modern technologies.
Q: Would Advanced Joint Support help in rheumatoid arthritis (RA)?
A: Advanced Joint Support might help support the joints in RA; however inflammation is the key in rheumatoid arthritis. Products that would be better for the inflammation include Green Lipped FFA, Inflammation Relief, Olive Leaf Extract and Longvida curcumin products.
Curcumin suppresses soluble tau dimers and corrects molecular chaperone, synaptic, and behavioral deficits in aged human tau transgenic mice.
J Biol Chem. 2013 Feb 8;288(6):4056-65.
Ma QL, Zuo X, Yang F, Ubeda OJ, Gant DJ, Alaverdyan M, Teng E, Hu S, Chen PP, Maiti P, Teter B, Cole GM, Frautschy SA.
The mechanisms underlying Tau-related synaptic and cognitive deficits and the interrelationships between Tau species, their clearance pathways, and synaptic impairments remain poorly understood. To gain insight into these mechanisms, we examined these interrelationships in aged non-mutant genomic human Tau mice, with established Tau pathology and neuron loss. We also examined how these interrelationships changed with an intervention by feeding mice either a control diet or one containing the brain permeable beta-amyloid and Tau aggregate binding molecule curcumin. Transgene-dependent elevations in soluble and insoluble phospho-Tau monomer and soluble Tau dimers accompanied deficits in behavior, hippocampal excitatory synaptic markers, and molecular chaperones (heat shock proteins (HSPs)) involved in Tau degradation and microtubule stability. In human Tau mice but not control mice, HSP70, HSP70/HSP72, and HSP90 were reduced in membrane-enriched fractions but not in cytosolic fractions. The synaptic proteins PSD95 and NR2B were reduced in dendritic fields and redistributed into perikarya, corresponding to changes observed by immunoblot. Curcumin selectively suppressed levels of soluble Tau dimers, but not of insoluble and monomeric phospho-Tau, while correcting behavioral, synaptic, and HSP deficits. Treatment increased PSD95 co-immunoprecipitating with NR2B and, independent of transgene, increased HSPs implicated in Tau clearance. It elevated HSP90 and HSC70 without increasing HSP mRNAs; that is, without induction of the heat shock response. Instead curcumin differentially impacted HSP90 client kinases, reducing Fyn without reducing Akt. In summary, curcumin reduced soluble Tau and elevated HSPs involved in Tau clearance, showing that even after tangles have formed, Tau-dependent behavioral and synaptic deficits can be corrected.
Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people.
Nutr J. 2012 Sep 26;11:79.
Disilvestro RA, Joseph E, Zhao S, Bomser J.
BACKGROUND: Curcumin extracts of turmeric are proposed to produce health benefits. To date, human intervention studies have focused mainly on people with existing health problems given high doses of poorly absorbed curcumin. The purpose of the current study was to check whether in healthy people, a low dose of a lipidated curcumin extract could alter wellness-related measures.
METHODS: The present study was conducted in healthy middle aged people (40-60 years old) with a low dose of curcumin (80 mg/day) in a lipidated form expected to have good absorption. Subjects were given either curcumin (N = 19) or placebo (N = 19) for 4 wk. Blood and saliva samples were taken before and after the 4 weeks and analyzed for a variety of blood and saliva measures relevant to health promotion.
RESULTS: Curcumin, but not placebo, produced the following statistically significant changes: lowering of plasma triglyceride values, lowering of salivary amylase levels, raising of salivary radical scavenging capacities, raising of plasma catalase activities, lowering of plasma beta amyloid protein concentrations, lowering of plasma sICAM readings, increased plasma myeloperoxidase without increased c-reactive protein levels, increased plasma nitric oxide, and decreased plasma alanine amino transferase activities.
CONCLUSION: Collectively, these results demonstrate that a low dose of a curcumin-lipid preparation can produce a variety of potentially health promoting effects in healthy middle aged people.
A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis.
Phytother Res. 2012 Nov;26(11):1719-25.
Chandran B, Goel A.
Curcumin is known to possess potent antiinflammatory and antiarthritic properties. This pilot clinical study evaluated the safety and effectiveness of curcumin alone, and in combination with diclofenac sodium in patients with active rheumatoid arthritis (RA). Forty-five patients diagnosed with RA were randomized into three groups with patients receiving curcumin (500 mg) and diclofenac sodium (50 mg) alone or their combination. The primary endpoints were reduction in Disease Activity Score (DAS) 28. The secondary endpoints included American College of Rheumatology (ACR) criteria for reduction in tenderness and swelling of joint scores. Patients in all three treatment groups showed statistically significant changes in their DAS scores. Interestingly, the curcumin group showed the highest percentage of improvement in overall DAS and ACR scores (ACR 20, 50 and 70) and these scores were significantly better than the patients in the diclofenac sodium group. More importantly, curcumin treatment was found to be safe and did not relate with any adverse events. Our study provides the first evidence for the safety and superiority of curcumin treatment in patients with active RA, and highlights the need for future large-scale trials to validate these findings in patients with RA and other arthritic conditions.
Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers.
J Agric Food Chem. 2010 Feb 24;58(4):2095-9
Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG.
Curcumin is the lipid-soluble antioxidant compound obtained from the rhizome of Curcuma longa Linn, also known as turmeric. Curcumin targets multiple chemotherapeutic and inflammatory pathways and has demonstrated safety and tolerability in humans, supporting its potential as a therapeutic agent; however, the clinical literature lacks conclusive evidence supporting its use as a therapeutic agent due to its low bioavailability in humans. The purpose of this study was to quantify plasma levels of free curcumin after dosing of a solid lipid curcumin particle (SLCP) formulation versus unformulated curcumin in healthy volunteers and to determine its tolerability and dose-plasma concentration relationship in late-stage osteosarcoma patients. Doses of 2, 3, and 4 g of SLCP were evaluated in 11 patients with osteosarcoma. Plasma curcumin levels were measured using a validated high-performance liquid chromatography method. The limit of detection of the assay was 1 ng/mL of curcumin. In healthy subjects, the mean peak concentration of curcumin achieved from dosing 650 mg of SLCP was 22.43 ng/mL, whereas plasma curcumin from dosing an equal quantity of unformulated 95% curcuminoids extract was not detected. In both healthy individuals and osteosarcoma patients, high interindividual variability in pharmacokinetics and nonlinear dose dependency was observed, suggesting potentially complex absorption kinetics. Overall, good tolerability was noted in both healthy and osteosarcoma groups.
Curcumin Structure-Function, Bioavailability, and Efficacy in Models of Neuroinflammation and Alzheimer’s Disease.
J Pharmacol Exp Ther. 2008 Jul;326(1):196-208.
Begum et al.
Curcumin can reduce inflammation and neurodegeneration, but its chemical instability and metabolism raise concerns, including whether the more stable metabolite tetrahydrocurcumin (TC) may mediate efficacy. We examined the antioxidant, anti-inflammatory, or anti-amyloidogenic effects of dietary curcumin and TC, either administered chronically to aged Tg2576 APPsw mice or acutely to lipopolysaccharide (LPS)-injected wild-type mice. Despite dramatically higher drug plasma levels after TC compared with curcumin gavage, resulting brain levels of parent compounds were similar, correlating with reduction in LPS-stimulated inducible nitric-oxide synthase, nitrotyrosine, F2 isoprostanes, and carbonyls. In both the acute (LPS) and chronic inflammation (Tg2576), TC and curcumin similarly reduced interleukin-1β. Despite these similarities, only curcumin was effective in reducing amyloid plaque burden, insoluble β-amyloid peptide (Aβ), and carbonyls. TC had no impact on plaques or insoluble Aβ, but both reduced Tris-buffered saline-soluble Aβ and phospho-c-Jun NH2-terminal kinase (JNK). Curcumin but not TC prevented Aβ aggregation. The TC metabolite was detected in brain and plasma from mice chronically fed the parent compound. These data indicate that the dienone bridge present in curcumin, but not in TC, is necessary to reduce plaque deposition and protein oxidation in an Alzheimer’s model. Nevertheless, TC did reduce neuroinflammation and soluble Aβ, effects that may be attributable to limiting JNK-mediated transcription. Because of its favorable safety profile and the involvement of misfolded proteins, oxidative damage, and inflammation in multiple chronic degenerative diseases, these data relating curcumin dosing to the blood and tissue levels required for efficacy should help translation efforts from multiple successful preclinical models.
Omega 3 DHA and a bioavailable curcumin formulation synergize for Alzheimer prevention.
39th Annual Meeting of the Society of Neuroscience , Chicago, IL October 2009.
Frautschy, SA et al.
Non-steroidal anti-inflammatory drugs (NSAIDs) reduce risk for Alzheimer’s disease (AD) and may work for prevention but significant side-effect concerns have motivated a search for safer alternatives for chronic use. One alternative, the omega-3 fatty acid DHA, appears promising based on both epidemiology and APP transgenic model work. Successful use of a second alternative, curcumin, an NSAID/ antioxidant used in traditional Indian and Asian medicines, has been hampered by extremely poor bioavailability. Here we report that a more bioavailable lipidated formulation of curcumin can be combined in a cocktail with the omega 3 fatty acid DHA to provide effective interventions in multiple animal models for AD. The curcumin cocktail improves cognitive function, pathology, signal transduction and synaptic deficits in multiple animal models for Alzheimer’s disease including APP Tg mice, 3xAD-Tg mice and htau Tg mice. Interventions have been synergistically effective in preventing cognitive deficits in Morris Water Maze and Y Maze as well as Aβ oligomer-induced insulin/neurotrophic factor inactivation, tau kinase activation and fyn/Tiam1/rac/PAK pathway defects related to synaptic deficits in vivo and in vitro. Further, while DHA alone is very effective in vitro and with early interventions in vivo, effective late stage cocktail interventions in AD model mice with significant pre-existing pathology, neuron loss and cognitive deficits are clearly dependent on the inclusion of the bioavailable lipidated curcumin. The added efficacy with curcumin may reflect a synergistic emulation of NSAID efficacy in suppressing arachidonic acid metabolites and direct binding of β-pleated amyloid structure. Unlike animal models that have pre-pathology cognitive deficits, clinical decline in minimal cognitive impairment and Alzheimer’s disease follows an extensive pro-dromal buildup of both beta amyloid and tau pathology. “Late stages” in transgenic models with extensive pathology better reflects the pathological status of humans at initial stages of clinically relevant cognitive decline. Therefore, success at “late stages” in AD models may be a better predictor of success in clinical trials aimed at prevention and early stage intervention.
Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions.
Anticancer Res. 2001 Jul-Aug;21(4B):2895-900.
Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, Hsieh CY.
Curcumin (diferuloylmethane), a yellow substance from the root of the plant Curcuma longa Linn., has been demonstrated to inhibit carcinogenesis of murine skin, stomach, intestine and liver. However, the toxicology, pharmacokinetics and biologically effective dose of curcumin in humans have not been reported. This prospective phase-I study evaluated these issues of curcumin in patients with one of the following five high-risk conditions: 1) recently resected urinary bladder cancer; 2) arsenic Bowen’s disease of the skin; 3) uterine cervical intraepithelial neoplasm (CIN); 4) oral leucoplakia; and 5) intestinal metaplasia of the stomach. Curcumin was taken orally for 3 months. Biopsy of the lesion sites was done immediately before and 3 months after starting curcumin treament. The starting dose was 500 mg/day. If no toxicity > or = grade II was noted in at least 3 successive patients, the dose was then escalated to another level in the order of 1,000, 2,000, 4,000, 8,000, and 12,000 mg/day. The concentration of curcumin in serum and urine was determined by high pressure liquid chromatography (HPLC). A total of 25 patients were enrolled in this study. There was no treatment-related toxicity up to 8,000 mg/day. Beyond 8,000 mg/day, the bulky volume of the drug was unacceptable to the patients. The serum concentration of curcumin usually peaked at 1 to 2 hours after oral intake of crucumin and gradually declined within 12 hours. The average peak serum concentrations after taking 4,000 mg, 6,000 mg and 8,000 mg of curcumin were 0.51 +/- 0.11 microM, 0.63 +/- 0.06 microM and 1.77 +/- 1.87 microM, respectively. Urinary excretion of curcumin was undetectable. One of 4 patients with CIN and 1 of 7 patients with oral leucoplakia proceeded to develop frank malignancies in spite of curcumin treatment. In contrast, histologic improvement of precancerous lesions was seen in 1 out of 2 patients with recently resected bladder cancer, 2 out of 7 patients of oral leucoplakia, 1 out of 6 patients of intestinal metaplasia of the stomach, I out of 4 patients with CIN and 2 out of 6 patients with Bowen’s disease. In conclusion, this study demonstrated that curcumin is not toxic to humans up to 8,000 mg/day when taken by mouth for 3 months. Our results also suggest a biologic effect of curcumin in the chemoprevention of cancer.